[Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005086
German
Original Title:
Brexucabtagen Autoleucel (rezidivierte oder refraktäre B-Zell-Vorläufer ALL)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-118.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-118_brexucabtagen-autoleucel_abd-konzept_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia
- Lymphoma
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Antineoplastic Agents, Immunological
- Registries
Keywords
- Brexucabtagene Autoleucel
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Registries
- Benefit Assessment
- Concept
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.